A Phase II, Multi-Centre Study, of Stereotactic Radiation Therapy for Oligo-Progression in Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy
Stereotactic radiation therapy (SRT) is a newer type of focused radiation therapy that precisely
and accurately delivers high dose radiation to a tumour, while sparing much of the nearby
normal organs. The use of stereotactic radiation therapy results in high rates of tumour
destruction with minimal side effects which are very well tolerated. Often stereotactic
radiation therapy has been used to try to cure patients who have an early stage cancer which has
not spread, but there is less experience with using it in patients with cancer which has
The purpose of this study is to measure how well stereotactic radiation therapy can destroy
kidney cancer tumours which are no longer being controlled by Sunitinib and to measure how
much longer such an approach will allow patients to stay on Sunitinib before needing to
switch to another medication. Stereotactic radiation therapy will be used to treat only the
growing tumours and then patients will continue with Sunitinib.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society